INT136514

Context Info Confidence 0.12 First Reported 2006 Last Reported 2009 Negated 0 Speculated 0 Reported most in Abstract Documents 4 Total Number 4 Disease Relevance 1.80 Pain Relevance 3.90

plasma membrane (Grm1, Grm5) signal transducer activity (Grm1, Grm5) nucleus (Grm1) cytoplasm (Grm5)

Anatomy Link Frequency neuropil 1 Grm1 (Rattus norvegicus) Grm5 (Rattus norvegicus)

Pain Link Frequency Relevance Heat antagonist 37 100.00 IPN 3 100.00 Morphine 9 98.96 tolerance 9 97.84 Analgesic 9 96.80 Pain 20 96.12 Dorsal horn 5 94.72 Spinal cord 9 94.24 Inflammation 6 93.08 nMDA receptor 7 81.08

Disease Link Frequency Relevance Heat Inflammatory Pain 3 100.00 Injury 3 97.44 Pain 20 96.12 INFLAMMATION 6 93.08 Ganglion Cysts 2 47.60 Depression 2 45.72 Nociception 7 5.00 Myelodysplastic Syndromes 2 5.00 Ketoacidosis 1 5.00 Decapitation 1 5.00

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Compelling anatomical and electrophysiological studies have indicated the presence of mGluR1 and mGluR5 in the neuropil of all the trigeminal nuclei [15].

mGluR1 Binding (presence) of mGluR5 in neuropil

1) Confidence 0.12 Published 2009 Journal Mol Pain Section Body Doc Link PMC2743647 Disease Relevance 0 Pain Relevance 0.32

The aims of the present study were to assess: (i) the role of mGlu1 and mGlu5 receptors in inflammatory pain using selective antagonist EMQMCM, 1.25-5 mg/kg, as the mGlu1 receptor antagonist, and MPEP or MTEP, 2.5-10 mg/kg, as mGlu5 receptor antagonist; (ii) the possible interaction between mGlu1 and mGlu5 receptor antagonists and morphine; and (iii) whether tolerance develops to the analgesic effects of these antagonists after prolonged treatment.

mGlu1 Binding (interaction) of mGlu5 associated with analgesic, antagonist, ipn, tolerance and morphine

2) Confidence 0.07 Published 2006 Journal Neuropharmacology Section Abstract Doc Link 16793067 Disease Relevance 0.61 Pain Relevance 1.20

The aims of the present study were to assess: (i) the role of mGlu1 and mGlu5 receptors in inflammatory pain using selective antagonist EMQMCM, 1.25-5 mg/kg, as the mGlu1 receptor antagonist, and MPEP or MTEP, 2.5-10 mg/kg, as mGlu5 receptor antagonist; (ii) the possible interaction between mGlu1 and mGlu5 receptor antagonists and morphine; and (iii) whether tolerance develops to the analgesic effects of these antagonists after prolonged treatment.

mGlu1 Binding (interaction) of mGlu5 associated with analgesic, antagonist, ipn, tolerance and morphine

3) Confidence 0.07 Published 2006 Journal Neuropharmacology Section Abstract Doc Link 16793067 Disease Relevance 0.61 Pain Relevance 1.20

The aims of the present study were to assess: (i) the role of mGlu1 and mGlu5 receptors in inflammatory pain using selective antagonist EMQMCM, 1.25-5 mg/kg, as the mGlu1 receptor antagonist, and MPEP or MTEP, 2.5-10 mg/kg, as mGlu5 receptor antagonist; (ii) the possible interaction between mGlu1 and mGlu5 receptor antagonists and morphine; and (iii) whether tolerance develops to the analgesic effects of these antagonists after prolonged treatment.

mGlu1 Binding (interaction) of mGlu5 associated with analgesic, antagonist, ipn, tolerance and morphine

4) Confidence 0.07 Published 2006 Journal Neuropharmacology Section Abstract Doc Link 16793067 Disease Relevance 0.58 Pain Relevance 1.18

General Comments

This test has worked.